Strategic Partnerships Leverage ongoing collaboration with Zenas BioPharma for ICP-054 IL-17A/AF inhibitor to accelerate co-development and regional commercialization, creating a ready-made path for joint launches in autoimmune indications.

Late Stage Pipeline Capitalize on late-stage assets such as orelabrutinib for BTK inhibition in autoimmune disease and mesutoclax for MDS/AML to pursue licensing or co-promotion deals with regional partners, leveraging Phase II/III data momentum.

Global Footprint With operations across Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States, target partner networks for regional distribution, commercial rights and local market access strategies in North America, Europe and Asia Pacific.

Autoimmune and Oncology Focus Recent data presentations at EULAR and ASCO highlight strength in autoimmune and oncology programs, supporting value proposition for hospitals, KOLs, and payers; align BD outreach to target disease areas with clear clinical and economic value stories.

Financial and Commercial Readiness Public listings on HKEX and SSE, plus solid revenue base, position InnoCare for milestone-driven partnerships, strategic investments or out-licensing agreements with favorable terms and rapid capital deployment for scale.